BRIEF-Ablynx expects Phase II results of rare blood disorder study in first half of 2014

BRUSSELS Mon Jan 13, 2014 1:46am EST

Related Topics

BRUSSELS Jan 13 (Reuters) - Ablynx NV : * Phaseii data on anti-vWF Nanobody, Caplacizumab,to treat acquired thrombotic thrombocytopenic purpura, expected in H1 2014 * Says if the results are promising, a phase III study is anticipated to commence in 2015

FILED UNDER: